Categories
Query Form
Posted on Apr 19, 2022
Dengvaxia is a dengue fever vaccine, which is presently approved for people aged between 9 – 45 years, living in areas having higher occurrences of the dengue fever. It is provided in 3 doses across the course of 1 year. Denvaxia prevents the dengue infections little more than half the time. This vaccine is only approved for the older children as the younger vaccinated kids may be at an increased risk of getting severe dengue & hospitalization 2 years post receiving this vaccine.
The WHO has stressed that the vaccine isn’t effective all by itself to curb dengue in the areas where the ailment is common. Controlling the mosquito count & human exposure to them still remains the most critical aspect of preventive measures.
Hence, presently, avoiding bites by infected mosquitos for prevention of the dengue fever remains the best measure for people staying or traveling to areas with prevalent dengue. Below suggestions should help us reduce our risk of mosquito bites if we live or travel to some tropical area where dengue is commonly prevalent: